FTC to study authorized generics
The Federal Trade Commission plans to investigate the likely short- and long-term competitive effects of authorized generic versions of brand drugs. FTC staffers have been authorized to subpoena about 80 drug companies, 10 authorized generic companies, and 100 independent generic manufacturers.
FTC to study authorized generics
The Federal Trade Commission plans to investigate the likely short- and long-term competitive effects of authorized generic versions of brand drugs. FTC staffers have been authorized to subpoena about 80 drug companies, 10 authorized generic companies, and 100 independent generic manufacturers. Public comments to be used to refine the research will be accepted until June 5. A final report is expected sometime next year.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
